Ultragenyx Pharmaceutical Inc. (RARE) · Sep 2, 2026 · Other events

Ultragenyx's Angelman trial fails both endpoints as apazunersen's future turns uncertain

Below the bar — Both primary efficacy endpoints missed; no treated-control efficacy difference

Ultragenyx's pivotal Angelman study missed both efficacy endpoints, putting apazunersen's program under review and triggering planned expense reductions.

The market was waiting for a binary Phase 3 verdict, not another development update. Aspire data were expected in the September–October 2026 window, and management had framed statistical success as meeting either the Bayley-4 cognition threshold or the MDRI threshold. There was no reliable published numerical consensus to compare against, so the clean benchmark is the study's predefined efficacy bar and the prior Phase 1/2 signal.

The readout is decisively below that bar: neither efficacy measure separated from control. The filing says Aspire “did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index.” 〔0〕 It further states that there were no treatment-control differences supporting efficacy in the Bayley cognition scores, MDRI net response, or the five individual MDRI components. 〔1〕

The result materially weakens the apazunersen investment case and creates an immediate capital-allocation overhang. Ultragenyx is not committing to continue the program; it will evaluate the asset's disposition, while also assessing “significant expense reductions.” 〔2〕 〔3〕 The safety result was not the problem—the observed profile was consistent with Phase 1/2—so the negative signal is concentrated in efficacy and the possibility that prior uncontrolled evidence does not translate into a controlled benefit. 〔4〕

What to watch next

Apazunersen program disposition decision

Original filing on SEC EDGAR

More Ultragenyx Pharmaceutical Inc. news

Ultragenyx's Angelman trial fails both endpoints as apazunersen's future turns uncertain | RARE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.